Breast Cancer Clinical Trial

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions

Summary

The objective of this study was to prove the bioequivalence of Letrozole Tablet under fed conditions.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to letrozole or any comparable or similar product.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

28

Study ID:

NCT01367626

Recruitment Status:

Completed

Sponsor:

Roxane Laboratories

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

PRACS Institute, Ltd.
Fargo North Dakota, 58104, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

28

Study ID:

NCT01367626

Recruitment Status:

Completed

Sponsor:


Roxane Laboratories

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider